检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨荣华[1] 虞敏晶[1] 徐玲玉[1] 张桂普[1]
机构地区:[1]苏州大学附属常州肿瘤医院乳腺外科,江苏省213001
出 处:《江苏医药》2012年第23期2857-2859,共3页Jiangsu Medical Journal
摘 要:目的分析雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体2(HER-2)三阴性乳腺癌的临床病理特征和预后。方法经病理确诊的乳腺癌患者613例分为三阴性乳腺癌组(A组,122例)和非三阴性乳腺癌组(B组,491例)。比较两组患者的临床病理特征、复发和远处转移及生存情况。结果 A组髓样癌发生率21.3%,组织学Ⅲ级占60.6%,p53基因阳性表达率73.7%,均明显高于B组的5.9%,30.9%,40.9%(P<0.05);A组淋巴结转移率高于B组(49.2%vs.40.1%)P<0.05);A组局部复发率和肝、肺转移率均显著高于B组(P<0.05)。生存分析显示,A组5年无瘤生存率和5年总生存率分别为65%和81%,均显著低于B组的76%和88%(P<0.05)。结论三阴性乳腺癌具有特定的临床特征,无瘤生存率和总生存率明显低于非三阴性乳腺癌患者。Objective To analyze the clinicopathological characteristics and prognosis of estrin receptor(ER),progestin receptor(PR) and human epidermal groth factor recepter 2(HER-2) triple negative breast cancer(TNBC).Methods A total of 613 patients with breast cancer confirmed by pathology were divided into two groups of A(122 cases with TNBC) and B(491 cases,with non-TNBC).The clinicopathological characteristics,recurrence and survival of the patients were analyzed.Results The incidence rates of medullary cancer and grade Ⅲ were higher in group A than those in group B(21.3% vs.5.9% and 60.6% vs.30.9%)(P0.05).The expression rate of p53 was higher in group A than that in group B(73.7% vs.40.9%)(P0.05).The local lymph node metastasis rate was higher in group A than that in group B(49.2% vs.40.1%)(P0.05).The local occurrence rate and lung and liver metastasis rates were significantly higher in group A than those in group B(P0.05).The 5-year disease-free and overall survival rate were significantly lower in group A than those in group B(65% vs.76% and 81% vs.88%)(P0.05).Conclusion TNBC has some specific clinicopathological characteristics.The disease-free and overall survival rates of TNBC patients are significantly lower than those of non-TNBC ones.
关 键 词:乳腺癌
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.13